Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 23Recruiting 15Terminated 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 57Magnetic Resonance Spectroscopy 39Carboplatin 32Cyclophosphamide 29Gemcitabine 28Bevacizumab 24pembrolizumab 23Cisplatin 23Biopsy 23Paclitaxel 22Standard of Care 21Radiotherapy 21Drug Therapy 21fludarabine 20Injections 20Capecitabine 20venetoclax 19Oxaliplatin 19Nivolumab 18Interviews as Topic 17toripalimab 16Dexamethasone 16Blood Specimen Collection 16Radiosurgery 14tislelizumab 13cemiplimab 13anlotinib 13Azacitidine 13Pemetrexed 12Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × tremelimumab × 90 days × Clear all
NCT06855225 2026-04-17

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Hoosier Cancer Research Network

Phase 2 Not yet recruiting
29 enrolled
Gastrointestinal

Liver Neoplasms

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

OHSU Knight Cancer Institute

Phase 2 Not yet recruiting
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡